Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Assessment and Management Strategies for Pneumonitis in Durvalumab Consolidation Post Chemoradiotherapy

March 6th 2025

This video discusses the clinical considerations around pneumonitis in patients undergoing chemoradiation and immunotherapy, including how to distinguish between radiation-induced and immune-related pneumonitis, and the importance of consulting specialists to avoid prematurely discontinuing treatment like durvalumab.

Consolidation Durvalumab in Unresectable Stage III NSCLC: Management Strategies and the Role of ctDNA

March 6th 2025

This video discusses evolving treatment paradigms for locally advanced lung cancer, highlighting the impact of trials like PACIFIC on the role of chemoradiotherapy and consolidation therapy with durvalumab, the potential integration of circulating tumor DNA (ctDNA) for personalized treatment decisions, and the implications for both surgical and nonsurgical patient populations.

Tailoring Chemoradiotherapy Approaches in Unresectable Stage III NSCLC

March 6th 2025

This segment transitions to discussing the management of unresectable non–small cell lung cancer (NSCLC), focusing on the distinctions between concurrent and sequential chemoradiation. It highlights patient selection, treatment tolerability, the role of advanced radiation technologies, and considerations for minimizing adverse effects while ensuring optimal outcomes.

Ensartinib Looks to Find a Place in ALK+ NSCLC Paradigm Alongside Approved TKIs

March 5th 2025

Alberto Chiappori, MD, details how to select between ensartinib and approved ALK TKIs for NSCLC, as well as considerations with ensartinib’s FDA approval.

Tumor-Agnostic Approvals of T-DXd and Repotrectinib Carry the Field Forward

March 5th 2025

Clinicians parse through the impacts of tumor-agnostic FDA approvals, examining T-DXd and repotrectinib's 2024 approvals in particular.

Dr Zhou on Frontline Ivonescimab vs Pembrolizumab in PD-L1+ Advanced NSCLC

March 3rd 2025

Caicun Zhou, MD, PhD, discusses data for ivonescimab vs pembrolizumab as first-line treatment for patients with PD-L1–positive advanced NSCLC.

CHMP Recommends Perioperative Durvalumab Regimen in Resectable NSCLC

March 3rd 2025

The CHMP has recommended the approval of perioperative durvalumab plus neoadjuvant chemotherapy for patients with resectable NSCLC.

Five Under 5: Top Oncology Videos for the Week of 2/23

March 2nd 2025

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

Looking Ahead in SCLC: ADCs and Other Novel Agents

February 28th 2025

Panelists discuss how emerging antibody-drug conjugate (ADC) data from TROPiCS-03 and IDeate-Lung01 suggest potential in extensive-stage small cell lung cancer (ES-SCLC), impacting sequencing with current therapies. T-cell engagers like BI 764532 and HPN328 may reshape treatment. MRI surveillance, per retrospective data and MAVERICK, offers an alternative to prophylactic cranial irradiation (PCI), though select factors may still justify PCI use.

Expert Perspectives on Tarlatamab in ES-SCLC

February 28th 2025

Panelists discuss how the DeLLphi-301 trial demonstrated that tarlatamab, administered biweekly at a 10 mg dose, achieved a 40% objective response rate in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). This led to its accelerated FDA approval in May 2024. Integrating tarlatamab into clinical practice may present challenges, including managing cytokine release syndrome and neurologic toxicities, as well as addressing financial considerations.

Updates in the Diagnosis and Management of HER2-Mutant NSCLC

February 27th 2025

On January 30, 2025, a group of thoracic oncologists gathered for an in-person workshop to discuss advances in diagnosing and treating non–small cell lung cancer (NSCLC) related to an HER2 mutation. The session was moderated by Joshua Sabari, MD; and Benjamin Levy, MD. As they focused on HER2 biomarker testing, treatment sequencing, and emerging therapies (including antibody-drug conjugates [ADCs] and TKIs), the faculty reviewed clinical trial data, shared real-world experiences, and debated evolving treatment strategies.

The OncFive: Top Oncology Articles for the Week of 2/16

February 22nd 2025

FDA grants priority review to zongertinib in HER2-mutant NSCLC and dordaviprone for recurrent H3K27M+ diffuse glioma, and more from OncLive this week.

Key Updates in the Treatment of ES-SCLC

February 20th 2025

Panelists discuss how recent real-world data comparing atezolizumab and durvalumab in extensive-stage non–small cell lung cancer (ES-NSCLC) informs treatment selection, though direct comparisons remain limited. Lurbinectedin is a key second-line option, with emerging combination strategies.

Expert Insights on Recent Advancements in LS-SCLC

February 20th 2025

Panelists discuss how the ADRIATIC regimen integrates immunotherapy post-chemoradiation in late-stage small cell lung cancer (LS-SCLC). In patients with paraneoplastic syndromes or immune disorders, immunotherapy requires caution. Prophylactic cranial irradiation (PCI) is considered for high-risk cases, while MRI surveillance is preferred for select patients to reduce neurotoxicity.

FDA Grants Priority Review to Zongertinib for HER2-Mutant Advanced NSCLC

February 19th 2025

The FDA has granted priority review to zongertinib for unresectable or metastatic HER2-mutant advanced NSCLC.

Neoadjuvant Nivolumab Plus Chemo Improves OS in Resectable NSCLC

February 19th 2025

Neoadjuvant nivolumab plus chemotherapy improved overall survival in resectable non–small cell lung cancer.

FDA Grants Fast Track Designation to IBI363 for Squamous NSCLC

February 17th 2025

The FDA granted fast track designation to IBI363 for squamous non–small cell lung cancer.

Over a Dozen FDA Approvals in 2024 Changed the Lung Cancer Field

February 12th 2025

This full list of 2024 FDA approvals in lung cancer features insights from experts who sat down with us throughout the year to discuss their significance.

Perioperative Pembrolizumab Wins Canadian Approval for Resectable NSCLC

February 11th 2025

Health Canada has approved perioperative pembrolizumab for resectable non–small cell lung cancer.

Five Under 5: Top Oncology Videos for the Week of 2/2

February 9th 2025

The top 5 videos of the week cover insights in lung cancer, multiple myeloma, breast cancer, and follicular lymphoma.